Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05283551 (ClinicalTrials.gov)	November 25, 2020	24/2/2022	Famciclovir in Multiple Sclerosis	A Phase 2 Open Label Clinical Trial to Determine the Effect of Famciclovir on Epstein-Barr Virus Activity as Measured by EBV Shedding in Saliva of Patients With Multiple Sclerosis.	Multiple Sclerosis	Drug: Famciclovir	Queen Mary University of London	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United Kingdom
2	EUCTR2019-000169-19-GB (EUCTR)	03/09/2019	05/06/2019	Clinical trial to determine the effect of Famciclovir on Epstein Barr virus levels in the saliva of patients with Multiple Sclerosis.	Clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in saliva of patients with Multiple Sclerosis. - Famciclovir in Multiple Sclerosis	Epstein Barr virus infection in people with multiple sclerosis. MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10014077;Term: EBV infection;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]	Trade Name: Famciclovir Product Name: Famciclovir INN or Proposed INN: Famciclovir Other descriptive name: 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester	Queen Mary University London	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	United Kingdom